Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-09-19
2011-12-20
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C548S953000
Reexamination Certificate
active
08080542
ABSTRACT:
The present invention relates to amides that have activity as SIP receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.
REFERENCES:
patent: 3329781 (1967-07-01), Wiser
patent: 4767896 (1988-08-01), Nigg et al.
patent: 5145865 (1992-09-01), Fujii et al.
patent: 5614531 (1997-03-01), Juraszyk et al.
patent: 5880284 (1999-03-01), Himmelsbach et al.
patent: 6384061 (2002-05-01), Lee et al.
patent: 6411326 (2002-06-01), Tabata
patent: 6541203 (2003-04-01), Mitchison
patent: 2002/0156074 (2002-10-01), Barvian et al.
patent: 2002/0183519 (2002-12-01), Nar et al.
patent: 2005/0014725 (2005-01-01), Mi et al.
patent: 2005/0113283 (2005-05-01), Solow-Cordero et al.
patent: 2006/0135786 (2006-06-01), Saha et al.
patent: 2006/0173043 (2006-08-01), Han et al.
patent: 2007/0173487 (2007-07-01), Saha et al.
patent: 2008/0015177 (2008-01-01), Saha et al.
patent: 2008/0027036 (2008-01-01), Burli et al.
patent: 2008/0064677 (2008-03-01), Saha et al.
patent: 2009/0285772 (2009-11-01), Phiasivongsa et al.
patent: 1 553 075 (2005-07-01), None
patent: 10-204059 (1998-08-01), None
patent: 10-204059 (1998-08-01), None
patent: WO 97/45402 (1997-12-01), None
patent: 02064616 (2002-08-01), None
patent: 03061567 (2003-07-01), None
patent: 03062252 (2003-07-01), None
patent: 03105771 (2003-12-01), None
patent: 2004048383 (2004-06-01), None
patent: 2004062663 (2004-07-01), None
patent: 2004113330 (2004-12-01), None
patent: 2005020882 (2005-03-01), None
patent: 2006064757 (2006-06-01), None
patent: 2007061458 (2007-05-01), None
patent: 2007109330 (2007-09-01), None
patent: 2007109334 (2007-09-01), None
patent: WO 2007/109334 (2007-09-01), None
patent: 2009038759 (2009-03-01), None
Abdel-Rahman, T.M. Mans. Sci. Bull. (A Chem), vol. 25, No. 1, Jun. 1998.
Traynor et al., 1995, “Modulation by μ-opioid agonists of guanosine-5′-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells,” Molecular Pharmacology, 47, 848-854.
Zemann et al., 2006, “Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720,” Blood, 107(4), 1454-1458.
Pan et al., 2006, “A monoselective sphingosine-1-phospate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model,” Chemistry & Biology, 13, 1227-1234.
Burli Roland
Cee Victor
Lanman Brian
Neira Susana C.
Yu Xiang
Amgen Inc.
Anderson Rebecca
Epix Pharmaceuticals Inc.
McDonnell Boehnen & Hulbert & Berghoff LLP
Otton Alicia L
LandOfFree
S1P receptor modulating compounds and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with S1P receptor modulating compounds and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and S1P receptor modulating compounds and use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4316045